We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


FY22 results point to progress across Tx and Dx

Lighthouse | 25 April 2023


Recent deals provide evidence of assay traction

Lighthouse | 21 April 2023

Arecor Therapeutics

Continued delivery with key AT278 data due in Q423

Update | 20 April 2023

Futura Medical

Gearing up for further launches in 2023

Lighthouse | 05 April 2023

Redx Pharma

Fundamentals intact with catalysts on the horizon

Lighthouse | 04 April 2023


Significant 2022 achievements catalyse a promising 2023

Update | 03 April 2023

Futura Medical

MED3000 soft launch in Europe, FDA approval now Q2

Lighthouse | 14 March 2023


Pursuing a multi-faceted Parsortix commercial opportunity

Outlook | 13 March 2023

Redx Pharma

‘004 mono insufficient in BTC; H223 combo is key

Lighthouse | 08 March 2023


Delivering commercially and strategically during FY22

Lighthouse | 02 March 2023
1 2 3 4 5 6 7 8 9 10 >
412 results found.